To date, approximately 80 common fragile sites (CFS) have been identified in the human genome (Ruiz-Herrera et al. 2006). Unlike rare fragile sites, which map to sites that are genetically altered in individuals, CFS occur at consistent genomic locations in particular cell types, which are defined by the paucity of replication initiation events at these loci (Letessier et al. 2011). DNA breaks at CFS, referred to as expression of the fragile site, can be induced via treatment with inhibitors of DNA replication, carcinogens, and environmental stresses (Lukusa and Fryns 2008). Several CFS colocalize with common deletions and translocations in tumors. Early efforts to find tumor suppressor genes encoded within fragile sites focused on FRA3Bat chromosomal location 3p14.2, the most frequently expressed human CFS. Perturbations at 3p14.2 had been noted in many cancers and the site includes the t(3;8) translocation breakpoint...
- Nishizaki M, Sasaki J, Fang B, Atkinson EN, Minna JD, Roth JA, et al. Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells. Cancer Res. 2004;64(16):5745–52.PubMedPubMedCentralCrossRefGoogle Scholar